Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014

[1] Ferlay J(2010)Estimate of worldwide burden of in 2008. Globocan 2008 Int J Cancer 127 2893-917

[2] Shin H(2014)Incfection and cancer: global distribution and burden of diseases Ann Glob Health. 80 384-92

[3] Baray F(2012)Global burden of human papillomavirus and related diseases Vaccine 30 F12-23

[4] Forman D(2012)Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities Vaccine 30 7-10

[5] Mathers C(2011)Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2675-86

[6] Parkin DM(2004)Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost Int J Cancer 109 418-24

[7] Oh JK(2013)Comprehensive control of human papilloma infections and related diseases Vaccine 31S F1-F31

[8] Weiderpass E(2013)Human papillomavirus and cervical cancer Lancet 382 889-99

[9] Forman D(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-27

[10] de Martel C(2007)Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2161-70

[1] Ferlay J(2010)Estimate of worldwide burden of in 2008. Globocan 2008 Int J Cancer 127 2893-917

[2] Shin H(2014)Incfection and cancer: global distribution and burden of diseases Ann Glob Health. 80 384-92

[3] Baray F(2012)Global burden of human papillomavirus and related diseases Vaccine 30 F12-23

[4] Forman D(2012)Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities Vaccine 30 7-10

[5] Mathers C(2011)Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2675-86

[6] Parkin DM(2004)Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost Int J Cancer 109 418-24

[7] Oh JK(2013)Comprehensive control of human papilloma infections and related diseases Vaccine 31S F1-F31

[8] Weiderpass E(2013)Human papillomavirus and cervical cancer Lancet 382 889-99

[9] Forman D(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-27

[10] de Martel C(2007)Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2161-70